The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
By J. Stangier, K. Rathgen, H. Stähle, D. Gansser, W. Roth. British Journal of Clinical Pharmacology, 2007
929 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Surgery
View Paper: https://www.semanticscholar.org/paper/b79446ecdf3c72de53281220e9ae900116925be1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Hematology
In Surgery
Citations in the corpus
- The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, background): “Studies of dabigatran reported no effect of weight on pharmacokinetic variables although analysis in older healthy individuals did not include very obese patients.(159,166,182) Pharmacokinetic data on both rivaroxaban and apixaban initially reported weight-dependent changes on volume distribution an”
- The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans (2008, methodology): “In a pharmacokinetic study in elderly subjects aged 65 years, a mean terminal half-life of 12.7 h was determined after 7 days of twice-daily treatment with 150 mg of dabigatran etexilate (Stangier et al., 2007b).”
- Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition) (2018, background): “A mild (CrCl 50–80 mL/min) to moderate (CrCl 30–49 mL/min) renal insufficiency increases the half-life up to 18 hours and 28 hours in severe renal insufficiency (CrCl 15–29 mL/min).(170,172,173)”
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity (2010, background): “The effect of dabigatran on the various coagulation assays has been investigated in vitro by the addition of defined concentrations of dabigatran to plasma from healthy human volunteers (2), as well as ex vivo using plasma samples from both healthy volunteers and patients (8, 14, 15).”